We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Eleni
Profyri
eleni.profyri.17@ucl.ac.uk
Dr
Anette
Schrag
a.schrag@ucl.ac.uk
Philip
Poku
p.poku@ucl.ac.uk
Extrapyramidal and movement disordersSchizophrenia, schizotypal and delusional disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The purpose of this study is to develop and evaluate the “Parkinson’s Disease Psychosis Rating Scale (PDP-RS)” together with other scales for Parkinson’s. The PDP-RS can be used to assess the severity of psychosis in patients with Parkinson’s. Psychosis means seeing or hearing things that are not there, having beliefs that things are happening they are not, or misperceptions such as seeing something that is there but looks like something else. Not all patients with Parkinson’s will develop psychosis. But, if they do, their doctor needs to know about it. It is not always possible to tell if a patient is having symptoms of psychosis just by looking at them or with the physical exam that your doctor performs. So, we need a way to help patients communicate with their doctors about these symptoms. We are therefore developing a rating scale to help describe the symptoms of psychosis in Parkinson’s and will evaluate them together with other scales in people with Parkinson’s. Participants will be invited to complete just one of the following study visits:
• Focus group: This will be a meeting where people with Parkinson's or care partners of people with Parkinson's will talk about symptoms such as those of psychosis.
OR
• Cognitive interview: The participant will review the developed version of the rating scale in an interview with open questions to get their opinion on the clarity of each item on the instrument and additional comments.
OR
• Validation: We will use the final version of the rating scale to assess participant's symptoms together with other scales and questionnaires.
These are sequential phases. The interviews will follow the focus groups and once this is completed we will follow with recruitment for the scale validation.
The participation may last between 1-2 hours.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Validation of outcome measures;
You can take part if:
You may not be able to take part if:
Medically unstable participants in an immediate postoperative period will be excluded.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Philip
Poku
p.poku@ucl.ac.uk
Dr
Anette
Schrag
a.schrag@ucl.ac.uk
Eleni
Profyri
eleni.profyri.17@ucl.ac.uk
The study is sponsored by University College London and funded by THE INTERNATIONAL PARKINSON AND MOVEMENT DISORDER SOCIETY INC .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 66056
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
